Answers are grounded in this paper and cite their sources.
In the twentieth century, antibiotics revolutionized medicine by making previously lethal infections curable and by enabling organ transplantation, chemotherapy, surgery, and newborn care. Less than a century after penicillin entered clinical use, however, antimicrobial resistance (AMR) has become one of the greatest threats to global health. This review traces the history of antibiotics and examines how the present resistance crisis arose, what it costs, and how it might be addressed. It is a narrative review based on a structured search of PubMed, Scopus, Web of Science, and Google Scholar for literature published up to date, supplemented by reports from the World Health Organization (WHO). It covers the pre-antibiotic period, the “golden age” of discovery (1940s–1960s), the “discovery void” that followed, and the current era of renewed but fragile innovation. The molecular mechanisms of resistance, the human, animal, and environmental drivers of the crisis, the worldwide burden of resistant infections, the economic barriers that have weakened the antibiotic pipeline, and the proposed solutions are summarized in five tables, including a timeline of major milestones, the WHO 2024 bacterial priority pathogens list, and a comparative appraisal of interventions. Bacterial AMR was directly responsible for approximately 1.27 million deaths and was associated with approximately 4.95 million deaths in 2019; the corresponding estimates for 2021 were 1.14 million and 4.71 million, and attributable deaths could reach approximately 1.9 million per year by 2050 if current trends continue. The burden falls disproportionately on older adults and on people in sub-Saharan Africa and South Asia. The crisis reflects a biological inevitability that is amplified by the overuse and misuse of antibiotics, inadequate infection control, and market failure. Our appraisal indicates that no single intervention is sufficient and that major evidence gaps remain, particularly for diagnostics, alternative therapies, and economic incentives in low- and middle-income countries. A coordinated One Health response that combines stewardship, surveillance, new discoveries, alternative therapies, and new economic incentives is necessary to preserve the effectiveness of antibiotics for future generations.
No takes yet. Share an insight, caveat, or question.
Billion et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: